The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge

Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remai...

Full description

Saved in:
Bibliographic Details
Published inJournal of breast cancer Vol. 21; no. 3; pp. 233 - 243
Main Authors Temian, Daiana Cosmina, Pop, Laura Ancuta, Irimie, Alexandra Iulia, Berindan-Neagoe, Ioana
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Breast Cancer Society 01.09.2018
Subjects
Review
DNA methylation
Triple negative breast neoplasms
Breast neoplasms
Untranslated RNA
Histone code
Online AccessGet full text
ISSN1738-6756
2092-9900
2092-9900
DOI10.4048/jbc.2018.21.e41

Cover

Abstract Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies-the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis-DNA methylation, histone modifications, and noncoding RNAs-advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.
AbstractList Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies–the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis–DNA methylation, histone modifications, and noncoding RNAs–advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.
Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies-the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis-DNA methylation, histone modifications, and noncoding RNAs-advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies-the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis-DNA methylation, histone modifications, and noncoding RNAs-advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.
Author Pop, Laura Ancuta
Temian, Daiana Cosmina
Irimie, Alexandra Iulia
Berindan-Neagoe, Ioana
AuthorAffiliation 4 MedFUTURE Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
2 Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
3 Division of Dental Propaedeutics, Aesthetic, Department of Prosthetic Dentistry and Dental Materials, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
1 Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
5 Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. I Chiricuta”, Cluj-Napoca, Romania
AuthorAffiliation_xml – name: 2 Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
– name: 5 Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. I Chiricuta”, Cluj-Napoca, Romania
– name: 3 Division of Dental Propaedeutics, Aesthetic, Department of Prosthetic Dentistry and Dental Materials, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
– name: 1 Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
– name: 4 MedFUTURE Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Author_xml – sequence: 1
  givenname: Daiana Cosmina
  orcidid: 0000-0003-0292-4218
  surname: Temian
  fullname: Temian, Daiana Cosmina
  organization: Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania., Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
– sequence: 2
  givenname: Laura Ancuta
  surname: Pop
  fullname: Pop, Laura Ancuta
  organization: Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
– sequence: 3
  givenname: Alexandra Iulia
  surname: Irimie
  fullname: Irimie, Alexandra Iulia
  organization: Division of Dental Propaedeutics, Aesthetic, Department of Prosthetic Dentistry and Dental Materials, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
– sequence: 4
  givenname: Ioana
  surname: Berindan-Neagoe
  fullname: Berindan-Neagoe, Ioana
  organization: Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania., MedFUTURE Research Center for Advanced Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania., Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. I Chiricuta”, Cluj-Napoca, Romania
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30275851$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1v1DAQxS1URLeFMzfkI5ds7diObQ5IdFVoxQoktJwtx5lsXbx2sJNW_e-b1ZZPCYnTHGZ-7z29OUFHMUVA6CUlS064Ortp3bImVC1rugROn6BFTXRdaU3IEVpQyVTVSNEco5NSbghpOJPyGTpmpJZCCbpAXzbXgC8Gv4UIo3cFpx5vsh8CVJ9ga0d_C9jGDp_bYkO19t8An2ewZcQrGx3kN3g15QxxxB9jugvQbeE5etrbUODF4zxFX99fbFaX1frzh6vVu3XlmGZjJZxQzjkuHbRdQ6jmrlW90I4KroVqe9XIXnPNWVtLzsE63XaUW8YlaRql2SkiB90pDvb-zoZghux3Nt8bSsy-HjPXY_b1mJqauZ4ZeXtAhqndQefm3Nn-wpL15s9N9Ndmm25NQ4Wiop4FXj8K5PR9gjKanS8OQrAR0lRmHyqkYJTv47363eunyY_u54Ozw4HLqZQM_X_EF38Rzo_zj9I-rA__5B4A2Oqojg
CitedBy_id crossref_primary_10_3389_fgene_2024_1440430
crossref_primary_10_2217_nnm_2023_0006
crossref_primary_10_3390_ph14070628
crossref_primary_10_1016_j_inoche_2024_113320
crossref_primary_10_1016_j_lfs_2022_120321
crossref_primary_10_1186_s40246_022_00436_6
crossref_primary_10_2174_0929867328666210707165530
crossref_primary_10_3389_fonc_2020_576362
crossref_primary_10_1016_j_tranon_2023_101639
crossref_primary_10_3390_ijerph18136930
crossref_primary_10_4236_abcr_2022_111001
crossref_primary_10_3390_ijms22094446
crossref_primary_10_3390_nu13041212
crossref_primary_10_1002_jcb_28565
crossref_primary_10_1080_09168451_2019_1709789
crossref_primary_10_1111_jcmm_16260
crossref_primary_10_1093_abbs_gmaa116
crossref_primary_10_29252_ibj_24_5_283
crossref_primary_10_1007_s11010_021_04191_5
crossref_primary_10_1186_s13058_021_01488_7
crossref_primary_10_1186_s13058_024_01800_1
crossref_primary_10_15407_ubj93_04_045
crossref_primary_10_1016_j_compbiolchem_2023_107902
crossref_primary_10_1038_s41419_020_02821_2
crossref_primary_10_3389_fonc_2020_00856
crossref_primary_10_2217_pgs_2019_0078
crossref_primary_10_1007_s10238_022_00955_5
crossref_primary_10_1007_s12272_021_01348_0
crossref_primary_10_1007_s13577_019_00273_1
crossref_primary_10_3390_diagnostics14171875
crossref_primary_10_2147_IJN_S269630
crossref_primary_10_2217_epi_2022_0033
crossref_primary_10_3389_fonc_2020_563779
crossref_primary_10_1016_j_chmed_2022_08_001
crossref_primary_10_1159_000509638
crossref_primary_10_1016_j_jtumed_2023_04_003
crossref_primary_10_1016_j_bbadis_2025_167783
crossref_primary_10_1016_j_neo_2024_100976
crossref_primary_10_1186_s13046_019_1231_y
crossref_primary_10_3390_ph18020207
crossref_primary_10_2217_epi_2019_0312
crossref_primary_10_1016_j_bcp_2019_05_001
crossref_primary_10_15407_ubj93_04_055
crossref_primary_10_3390_ijms232315429
crossref_primary_10_1016_j_trecan_2020_09_004
crossref_primary_10_2174_1566524021666211206092437
crossref_primary_10_1016_j_breast_2022_08_012
Cites_doi 10.1038/ncomms6899
10.1007/s10911-011-9225-1
10.1038/35021093
10.18632/oncotarget.9622
10.1371/journal.pone.0120936
10.1186/s13045-018-0576-6
10.1056/NEJMra1001389
10.1093/annonc/mdt284
10.1093/carcin/bgv087
10.1186/s12864-018-4533-0
10.1158/1078-0432.CCR-09-1039
10.3747/co.v18i4.824
10.1016/j.ajpath.2012.03.019
10.1186/s13058-016-0690-8
10.1017/erm.2016.17
10.1038/nrc.2015.21
10.3233/BD-2010-0319
10.1093/carcin/bgu133
10.1158/0008-5472.CAN-08-3907
10.1371/journal.pone.0098930
10.7243/2049-7962-3-2
10.1371/journal.pone.0167016
10.1158/1535-7163.MCT-14-0778
10.1073/pnas.191367098
10.1634/theoncologist.2011-S1-61
10.18632/oncotarget.19205
10.1002/path.4280
10.1038/nrd4286
10.2147/OTT.S110719
10.1007/s11010-013-1688-5
10.1038/onc.2014.363
10.1186/s13058-015-0550-y
10.3892/mmr.2014.3089
10.1002/path.2629
10.18632/oncotarget.19744
10.1016/j.cell.2007.01.029
10.1002/ijc.29347
10.1002/gcc.22422
10.18632/oncotarget.9505
10.1080/15384047.2015.1040957
10.18632/oncotarget.13814
10.1186/bcr3192
10.1186/s13058-015-0534-y
10.1016/j.mam.2012.07.018
10.3390/molecules20033898
10.1038/nature16508
10.3390/ijms161226090
10.18632/oncotarget.8384
10.1158/1078-0432.CCR-14-0432
10.1016/j.coi.2011.12.009
10.18632/oncotarget.14465
10.1074/jbc.M117.811463
10.18632/oncotarget.23169
10.18632/oncotarget.1682
10.1371/journal.pone.0157368
10.1007/s13402-015-0239-3
10.1002/jcp.24991
10.1097/MD.0000000000003783
10.1158/0008-5472.CAN-12-4306
10.18632/oncotarget.3441
10.1002/emmm.201100136
10.1016/j.cellsig.2016.02.006
10.1007/s10549-011-1409-2
10.1007/978-1-4939-1804-1_1
10.3389/fgene.2015.00002
10.1200/JCO.2010.30.1010
10.1172/JCI45014
10.3322/caac.21442
10.1186/1476-4598-7-15
10.1016/j.breast.2017.11.006
10.2217/epi-2018-0008
10.1245/s10434-013-3205-1
10.1002/mc.22237
10.1038/srep33435
10.18632/oncotarget.2454
10.1038/oncsis.2012.17
10.1038/ncomms6987
10.1186/s12885-016-2683-5
10.1186/bcr2098
10.1038/bjc.2013.144
10.1007/s10549-014-3089-1
10.1074/jbc.M116.738666
10.4048/jbc.2016.19.3.223
10.1186/bcr2590
10.18632/oncotarget.9804
10.1016/j.gene.2017.10.018
10.1016/j.breast.2013.08.007
10.18632/oncotarget.4419
10.4161/epi.22561
10.1007/978-3-662-45758-0_255
10.1038/nature08975
10.1038/nature11412
ContentType Journal Article
Copyright 2018 Korean Breast Cancer Society 2018 Korean Breast Cancer Society
Copyright_xml – notice: 2018 Korean Breast Cancer Society 2018 Korean Breast Cancer Society
DBID AAYXX
CITATION
NPM
7X8
5PM
ADTOC
UNPAY
DOI 10.4048/jbc.2018.21.e41
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2092-9900
EndPage 243
ExternalDocumentID 10.4048/jbc.2018.21.e41
PMC6158152
30275851
10_4048_jbc_2018_21_e41
Genre Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: 4995/16/08.03.2016
GroupedDBID ---
5-W
5GY
8JR
8XY
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
DU5
EF.
GROUPED_DOAJ
HYE
KQ8
M48
O5R
O5S
PGMZT
RPM
NPM
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c393t-5c58ccc47cebd60194cb8f59c154958bf867f94943b2744eac9bd14a347066893
IEDL.DBID M48
ISSN 1738-6756
2092-9900
IngestDate Wed Oct 01 16:23:01 EDT 2025
Thu Aug 21 18:27:20 EDT 2025
Fri Jul 11 15:49:56 EDT 2025
Wed Feb 19 02:43:30 EST 2025
Thu Apr 24 23:01:48 EDT 2025
Tue Jul 01 01:56:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords DNA methylation
Triple negative breast neoplasms
Breast neoplasms
Untranslated RNA
Histone code
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c393t-5c58ccc47cebd60194cb8f59c154958bf867f94943b2744eac9bd14a347066893
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0003-0292-4218
OpenAccessLink https://proxy.k.utb.cz/login?url=http://ejbc.kr/Synapse/Data/PDFData/0096JBC/jbc-21-233.pdf
PMID 30275851
PQID 2115753149
PQPubID 23479
PageCount 11
ParticipantIDs unpaywall_primary_10_4048_jbc_2018_21_e41
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6158152
proquest_miscellaneous_2115753149
pubmed_primary_30275851
crossref_primary_10_4048_jbc_2018_21_e41
crossref_citationtrail_10_4048_jbc_2018_21_e41
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-09-01
PublicationDateYYYYMMDD 2018-09-01
PublicationDate_xml – month: 09
  year: 2018
  text: 2018-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of breast cancer
PublicationTitleAlternate J Breast Cancer
PublicationYear 2018
Publisher Korean Breast Cancer Society
Publisher_xml – name: Korean Breast Cancer Society
References Lehmann (10.4048/jbc.2018.21.e41_ref12) 2011; 121
Wu (10.4048/jbc.2018.21.e41_ref93) 2016; 7
Liu (10.4048/jbc.2018.21.e41_ref46) 2016; 18
Burstein (10.4048/jbc.2018.21.e41_ref14) 2015; 21
Ahn (10.4048/jbc.2018.21.e41_ref16) 2016; 19
Robichaux (10.4048/jbc.2018.21.e41_ref25) 2014; 16
Palmieri (10.4048/jbc.2018.21.e41_ref88) 2009; 15
Chiorean (10.4048/jbc.2018.21.e41_ref3) 2013; 22
Liu (10.4048/jbc.2018.21.e41_ref51) 2014; 11
Zhu (10.4048/jbc.2018.21.e41_ref90) 2016; 95
Lavigne (10.4048/jbc.2018.21.e41_ref75) 2014; 9
Sahni (10.4048/jbc.2018.21.e41_ref71) 2016; 291
Wu (10.4048/jbc.2018.21.e41_ref91) 2015; 230
Elsheikh (10.4048/jbc.2018.21.e41_ref21) 2009; 69
Stefansson (10.4048/jbc.2018.21.e41_ref34) 2012; 7
Cancer Genome Atlas Network (10.4048/jbc.2018.21.e41_ref40) 2012; 490
Sunami (10.4048/jbc.2018.21.e41_ref42) 2008; 10
Lord (10.4048/jbc.2018.21.e41_ref30) 2016; 16
Kong (10.4048/jbc.2018.21.e41_ref38) 2015; 8
Tsouko (10.4048/jbc.2018.21.e41_ref61) 2015; 36
Braicu (10.4048/jbc.2018.21.e41_ref26) 2016; 18
Basse (10.4048/jbc.2018.21.e41_ref18) 2015; 137
Fkih M'hamed (10.4048/jbc.2018.21.e41_ref56) 2015; 38
Festuccia (10.4048/jbc.2018.21.e41_ref94) 2018; 11
Mathe (10.4048/jbc.2018.21.e41_ref63) 2015; 16
Branham (10.4048/jbc.2018.21.e41_ref27) 2012; 1
Greenup (10.4048/jbc.2018.21.e41_ref28) 2013; 20
Perou (10.4048/jbc.2018.21.e41_ref10) 2011; 16
Sørlie (10.4048/jbc.2018.21.e41_ref5) 2001; 98
Senkus (10.4048/jbc.2018.21.e41_ref6) 2013; 24
Sahai (10.4048/jbc.2018.21.e41_ref69) 2016; 7
Harburg (10.4048/jbc.2018.21.e41_ref24) 2011; 16
Gregoire (10.4048/jbc.2018.21.e41_ref74) 2016; 16
Hughes (10.4048/jbc.2018.21.e41_ref43) 2013; 73
Vázquez (10.4048/jbc.2018.21.e41_ref73) 2017; 8
Moody (10.4048/jbc.2018.21.e41_ref66) 2018; 293
Wu (10.4048/jbc.2018.21.e41_ref92) 2016; 7
Wang (10.4048/jbc.2018.21.e41_ref54) 2015; 6
Pop (10.4048/jbc.2018.21.e41_ref29) 2018; 38
Kagara (10.4048/jbc.2018.21.e41_ref39) 2012; 181
Lips (10.4048/jbc.2018.21.e41_ref31) 2013; 108
Gupta (10.4048/jbc.2018.21.e41_ref52) 2010; 464
Kanwal (10.4048/jbc.2018.21.e41_ref17) 2015; 1238
Terranova-Barberio (10.4048/jbc.2018.21.e41_ref86) 2017; 8
Braicu (10.4048/jbc.2018.21.e41_ref81) 2015; 10
Weigelt (10.4048/jbc.2018.21.e41_ref11) 2010; 220
Foulkes (10.4048/jbc.2018.21.e41_ref8) 2010; 363
Zhuang (10.4048/jbc.2018.21.e41_ref53) 2015; 54
Jadaliha (10.4048/jbc.2018.21.e41_ref49) 2016; 7
Humphries (10.4048/jbc.2018.21.e41_ref60) 2014; 35
Braicu (10.4048/jbc.2018.21.e41_ref82) 2013; 381
Schech (10.4048/jbc.2018.21.e41_ref87) 2015; 14
Palazzo (10.4048/jbc.2018.21.e41_ref22) 2015; 6
Roll (10.4048/jbc.2018.21.e41_ref44) 2008; 7
Sandhu (10.4048/jbc.2018.21.e41_ref45) 2012; 131
Ocaña (10.4048/jbc.2018.21.e41_ref67) 2017; 8
Wang (10.4048/jbc.2018.21.e41_ref79) 2016; 28
Tate (10.4048/jbc.2018.21.e41_ref83) 2012; 14
Lehmann (10.4048/jbc.2018.21.e41_ref13) 2016; 11
Murria (10.4048/jbc.2018.21.e41_ref32) 2015; 5
Stirzaker (10.4048/jbc.2018.21.e41_ref23) 2015; 6
Perou (10.4048/jbc.2018.21.e41_ref4) 2000; 406
Tammen (10.4048/jbc.2018.21.e41_ref19) 2013; 34
Filippakopoulos (10.4048/jbc.2018.21.e41_ref68) 2014; 13
Jones (10.4048/jbc.2018.21.e41_ref20) 2007; 128
Mori (10.4048/jbc.2018.21.e41_ref36) 2016; 11
Khaled (10.4048/jbc.2018.21.e41_ref65) 2015; 6
Xi (10.4048/jbc.2018.21.e41_ref64) 2018; 19
Mekala (10.4048/jbc.2018.21.e41_ref89) 2018; 641
Gierach (10.4048/jbc.2018.21.e41_ref2) 2010; 32
Kumaraswamy (10.4048/jbc.2018.21.e41_ref57) 2015; 34
Gasparini (10.4048/jbc.2018.21.e41_ref55) 2014; 5
Mathe (10.4048/jbc.2018.21.e41_ref37) 2016; 6
Sharma (10.4048/jbc.2018.21.e41_ref33) 2014; 3
Li (10.4048/jbc.2018.21.e41_ref77) 2018; 10
Mottamal (10.4048/jbc.2018.21.e41_ref78) 2015; 20
Shen (10.4048/jbc.2018.21.e41_ref47) 2015; 6
Topalian (10.4048/jbc.2018.21.e41_ref85) 2012; 24
Lachapelle (10.4048/jbc.2018.21.e41_ref7) 2011; 18
Chen (10.4048/jbc.2018.21.e41_ref48) 2015; 16
Siegel (10.4048/jbc.2018.21.e41_ref1) 2018; 68
Holm (10.4048/jbc.2018.21.e41_ref41) 2010; 12
Jézéquel (10.4048/jbc.2018.21.e41_ref15) 2015; 17
Shu (10.4048/jbc.2018.21.e41_ref70) 2016; 529
Min (10.4048/jbc.2018.21.e41_ref84) 2015; 17
Su (10.4048/jbc.2018.21.e41_ref50) 2014; 5
Li (10.4048/jbc.2018.21.e41_ref62) 2017; 8
Healey (10.4048/jbc.2018.21.e41_ref76) 2014; 147
Pileczki (10.4048/jbc.2018.21.e41_ref80) 2016; 9
Lehmann (10.4048/jbc.2018.21.e41_ref9) 2014; 232
Garcia (10.4048/jbc.2018.21.e41_ref58) 2011; 3
Nieto-Jiménez (10.4048/jbc.2018.21.e41_ref72) 2017; 8
Damiano (10.4048/jbc.2018.21.e41_ref59) 2017; 56
Veeck (10.4048/jbc.2018.21.e41_ref35) 2010; 28
29486795 - J Hematol Oncol. 2018 Feb 27;11(1):32
27956838 - Onco Targets Ther. 2016 Nov 11;9:6921-6933
27223259 - Oncotarget. 2016 Jun 21;7(25):38270-38281
25224916 - Breast Cancer Res Treat. 2014 Oct;147(3):639-51
25641231 - Nat Commun. 2015 Feb 02;6:5899
29263092 - J Biol Chem. 2018 Feb 9;293(6):2125-2136
27310713 - PLoS One. 2016 Jun 16;11(6):e0157368
23069641 - Epigenetics. 2012 Nov;7(11):1225-9
24751816 - Nat Rev Drug Discov. 2014 May;13(5):337-56
29156719 - Oncotarget. 2017 Jul 12;8(49):85276-85289
25996380 - Cancer Biol Ther. 2015;16(6):856-65
26975198 - Breast Cancer Res. 2016 Mar 15;18(1):33
26328265 - Am J Cancer Res. 2015 Jun 15;5(7):2330-43
26037781 - Mol Cancer Ther. 2015 Aug;14(8):1848-57
29050361 - Oncotarget. 2017 Aug 1;8(41):71285-71291
25328122 - Mol Carcinog. 2015 Dec;54(12):1656-67
22236695 - Curr Opin Immunol. 2012 Apr;24(2):207-12
25808524 - J Cell Physiol. 2015 Nov;230(11):2683-94
25417703 - Oncogene. 2015 Aug 13;34(33):4333-46
25888415 - Breast Cancer Res. 2015 Mar 07;17:33
25887482 - Breast Cancer Res. 2015 Mar 20;17:43
25738536 - Molecules. 2015 Mar 02;20(3):3898-941
22906839 - Mol Aspects Med. 2013 Jul-Aug;34(4):753-64
22613095 - Breast Cancer Res. 2012 May 21;14(3):R79
27817751 - Expert Rev Mol Med. 2016 Nov 7;18:e18
20565864 - Breast Cancer Res. 2010;12(3):R36
25516208 - Mol Med Rep. 2015 Apr;11(4):3155-9
27717206 - Genes Chromosomes Cancer. 2017 Feb;56(2):147-158
27283767 - Oncotarget. 2016 Aug 16;7(33):53997-54009
26088362 - Carcinogenesis. 2015 Sep;36(9):1051-60
24114677 - J Pathol. 2014 Jan;232(2):142-50
27250026 - Oncotarget. 2016 Jun 28;7(26):40418-40436
21818544 - J Mammary Gland Biol Neoplasia. 2011 Sep;16(3):257-70
29202330 - Breast. 2018 Apr;38:30-38
20393566 - Nature. 2010 Apr 15;464(7291):1071-6
25410431 - Int J Cancer. 2015 Dec 15;137(12):2785-94
24925028 - Carcinogenesis. 2014 Oct;35(10):2254-63
21965309 - Breast Dis. 2010;32(1-2):5-24
26876786 - Cell Signal. 2016 May;28(5):506-515
21067385 - N Engl J Med. 2010 Nov 11;363(20):1938-48
21359954 - Breast Cancer Res Treat. 2012 Jan;131(2):385-99
25883211 - Oncotarget. 2015 May 10;6(13):11150-61
29458327 - BMC Genomics. 2018 Feb 20;19(1):150
25421652 - Methods Mol Biol. 2015;1238:3-25
20679605 - J Clin Oncol. 2010 Oct 10;28(29):e563-4; author reply e565-6
18221536 - Mol Cancer. 2008 Jan 25;7:15
26735014 - Nature. 2016 Jan 21;529(7586):413-417
29371976 - Oncotarget. 2017 Dec 12;8(69):114156-114172
17320506 - Cell. 2007 Feb 23;128(4):683-92
27581651 - BMC Cancer. 2016 Aug 31;16:700
19927298 - J Pathol. 2010 Jan;220(2):263-80
27227949 - Medicine (Baltimore). 2016 May;95(21):e3783
25849487 - PLoS One. 2015 Apr 07;10(4):e0120936
23881244 - Mol Cell Biochem. 2013 Sep;381(1-2):61-8
22626806 - Am J Pathol. 2012 Jul;181(1):257-67
23970019 - Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23
26392359 - Cell Oncol (Dordr). 2015 Dec;38(6):433-42
21874112 - Curr Oncol. 2011 Aug;18(4):161-4
11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
23552734 - Oncogenesis. 2012 Jul 02;1:e17
23558900 - Br J Cancer. 2013 May 28;108(10):2172-7
25296969 - Oncotarget. 2014 Oct 30;5(20):9864-76
18485221 - Breast Cancer Res. 2008;10(3):R46
21472990 - EMBO Mol Med. 2011 May;3(5):279-90
25674102 - Front Genet. 2015 Jan 26;6:2
21633166 - J Clin Invest. 2011 Jul;121(7):2750-67
27671774 - Sci Rep. 2016 Sep 27;6:33435
19366799 - Cancer Res. 2009 May 1;69(9):3802-9
26617826 - Int J Clin Exp Pathol. 2015 Sep 01;8(9):11076-83
26078338 - Oncotarget. 2015 Aug 28;6(25):21730-9
28061448 - Oncotarget. 2017 Mar 21;8(12):19478-19490
24318963 - Curr Top Behav Neurosci. 2014;16:19-48
23975317 - Ann Surg Oncol. 2013 Oct;20(10):3254-8
23801749 - Cancer Res. 2013 Oct 1;73(19):5858-68
27935867 - Oncotarget. 2017 Jan 31;8(5):7598-7613
19789319 - Clin Cancer Res. 2009 Oct 1;15(19):6148-57
29480027 - Epigenomics. 2018 Jun;10(6):765-783
25208879 - Clin Cancer Res. 2015 Apr 1;21(7):1688-98
29038000 - Gene. 2018 Jan 30;641:248-258
27029062 - Oncotarget. 2016 May 10;7(19):27158-75
29313949 - CA Cancer J Clin. 2018 Jan;68(1):7-30
26775620 - Nat Rev Cancer. 2016 Feb;16(2):110-20
27721871 - J Breast Cancer. 2016 Sep;19(3):223-230
25177489 - J Cancer Ther Res. 2014 Mar 19;3(2):1-11
23000897 - Nature. 2012 Oct 4;490(7418):61-70
24911873 - PLoS One. 2014 Jun 09;9(6):e98930
10963602 - Nature. 2000 Aug 17;406(6797):747-52
25574598 - Nat Commun. 2015 Jan 09;6:5987
24632568 - Oncotarget. 2014 Mar 15;5(5):1174-84
24063766 - Breast. 2013 Dec;22(6):1026-33
26633365 - Int J Mol Sci. 2015 Nov 30;16(12):28347-76
27977696 - PLoS One. 2016 Dec 15;11(12):e0167016
21278442 - Oncologist. 2011;16 Suppl 1:61-70
27650498 - J Biol Chem. 2016 Nov 4;291(45):23756-23768
References_xml – volume: 6
  start-page: 5899
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref23
  publication-title: Nat Commun
  doi: 10.1038/ncomms6899
– volume: 16
  start-page: 257
  year: 2011
  ident: 10.4048/jbc.2018.21.e41_ref24
  publication-title: J Mammary Gland Biol Neoplasia
  doi: 10.1007/s10911-011-9225-1
– volume: 406
  start-page: 747
  year: 2000
  ident: 10.4048/jbc.2018.21.e41_ref4
  publication-title: Nature
  doi: 10.1038/35021093
– volume: 7
  start-page: 40418
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref49
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9622
– volume: 10
  start-page: e0120936
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref81
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0120936
– volume: 11
  start-page: 32
  year: 2018
  ident: 10.4048/jbc.2018.21.e41_ref94
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-018-0576-6
– volume: 363
  start-page: 1938
  year: 2010
  ident: 10.4048/jbc.2018.21.e41_ref8
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1001389
– volume: 24
  start-page: vi7
  issue: Suppl 6
  year: 2013
  ident: 10.4048/jbc.2018.21.e41_ref6
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt284
– volume: 36
  start-page: 1051
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref61
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgv087
– volume: 19
  start-page: 150
  year: 2018
  ident: 10.4048/jbc.2018.21.e41_ref64
  publication-title: BMC Genomics
  doi: 10.1186/s12864-018-4533-0
– volume: 15
  start-page: 6148
  year: 2009
  ident: 10.4048/jbc.2018.21.e41_ref88
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1039
– volume: 18
  start-page: 161
  year: 2011
  ident: 10.4048/jbc.2018.21.e41_ref7
  publication-title: Curr Oncol
  doi: 10.3747/co.v18i4.824
– volume: 181
  start-page: 257
  year: 2012
  ident: 10.4048/jbc.2018.21.e41_ref39
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2012.03.019
– volume: 18
  start-page: 33
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref46
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-016-0690-8
– volume: 5
  start-page: 2330
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref32
  publication-title: Am J Cancer Res
– volume: 18
  start-page: e18
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref26
  publication-title: Expert Rev Mol Med
  doi: 10.1017/erm.2016.17
– volume: 16
  start-page: 110
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref30
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2015.21
– volume: 32
  start-page: 5
  year: 2010
  ident: 10.4048/jbc.2018.21.e41_ref2
  publication-title: Breast Dis
  doi: 10.3233/BD-2010-0319
– volume: 35
  start-page: 2254
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref60
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgu133
– volume: 69
  start-page: 3802
  year: 2009
  ident: 10.4048/jbc.2018.21.e41_ref21
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-3907
– volume: 9
  start-page: e98930
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref75
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0098930
– volume: 3
  start-page: 1
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref33
  publication-title: J Cancer Ther Res
  doi: 10.7243/2049-7962-3-2
– volume: 11
  start-page: e0167016
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref36
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0167016
– volume: 8
  start-page: 11076
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref38
  publication-title: Int J Clin Exp Pathol
– volume: 14
  start-page: 1848
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref87
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-14-0778
– volume: 98
  start-page: 10869
  year: 2001
  ident: 10.4048/jbc.2018.21.e41_ref5
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.191367098
– volume: 16
  start-page: 61
  issue: Suppl 1
  year: 2011
  ident: 10.4048/jbc.2018.21.e41_ref10
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2011-S1-61
– volume: 8
  start-page: 85276
  year: 2017
  ident: 10.4048/jbc.2018.21.e41_ref62
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19205
– volume: 232
  start-page: 142
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref9
  publication-title: J Pathol
  doi: 10.1002/path.4280
– volume: 13
  start-page: 337
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref68
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4286
– volume: 9
  start-page: 6921
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref80
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S110719
– volume: 381
  start-page: 61
  year: 2013
  ident: 10.4048/jbc.2018.21.e41_ref82
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1688-5
– volume: 34
  start-page: 4333
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref57
  publication-title: Oncogene
  doi: 10.1038/onc.2014.363
– volume: 17
  start-page: 43
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref15
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-015-0550-y
– volume: 11
  start-page: 3155
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref51
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2014.3089
– volume: 220
  start-page: 263
  year: 2010
  ident: 10.4048/jbc.2018.21.e41_ref11
  publication-title: J Pathol
  doi: 10.1002/path.2629
– volume: 8
  start-page: 71285
  year: 2017
  ident: 10.4048/jbc.2018.21.e41_ref67
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19744
– volume: 128
  start-page: 683
  year: 2007
  ident: 10.4048/jbc.2018.21.e41_ref20
  publication-title: Cell
  doi: 10.1016/j.cell.2007.01.029
– volume: 137
  start-page: 2785
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref18
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29347
– volume: 56
  start-page: 147
  year: 2017
  ident: 10.4048/jbc.2018.21.e41_ref59
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.22422
– volume: 7
  start-page: 38270
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref92
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9505
– volume: 16
  start-page: 856
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref48
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2015.1040957
– volume: 8
  start-page: 7598
  year: 2017
  ident: 10.4048/jbc.2018.21.e41_ref73
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13814
– volume: 14
  start-page: R79
  year: 2012
  ident: 10.4048/jbc.2018.21.e41_ref83
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3192
– volume: 17
  start-page: 33
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref84
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-015-0534-y
– volume: 34
  start-page: 753
  year: 2013
  ident: 10.4048/jbc.2018.21.e41_ref19
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2012.07.018
– volume: 20
  start-page: 3898
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref78
  publication-title: Molecules
  doi: 10.3390/molecules20033898
– volume: 529
  start-page: 413
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref70
  publication-title: Nature
  doi: 10.1038/nature16508
– volume: 16
  start-page: 28347
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref63
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms161226090
– volume: 7
  start-page: 27158
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref93
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8384
– volume: 21
  start-page: 1688
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref14
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-0432
– volume: 24
  start-page: 207
  year: 2012
  ident: 10.4048/jbc.2018.21.e41_ref85
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2011.12.009
– volume: 8
  start-page: 19478
  year: 2017
  ident: 10.4048/jbc.2018.21.e41_ref72
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14465
– volume: 293
  start-page: 2125
  year: 2018
  ident: 10.4048/jbc.2018.21.e41_ref66
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M117.811463
– volume: 8
  start-page: 114156
  year: 2017
  ident: 10.4048/jbc.2018.21.e41_ref86
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.23169
– volume: 5
  start-page: 1174
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref55
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.1682
– volume: 11
  start-page: e0157368
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref13
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0157368
– volume: 38
  start-page: 433
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref56
  publication-title: Cell Oncol (Dordr)
  doi: 10.1007/s13402-015-0239-3
– volume: 230
  start-page: 2683
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref91
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.24991
– volume: 95
  start-page: e3783
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref90
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000003783
– volume: 73
  start-page: 5858
  year: 2013
  ident: 10.4048/jbc.2018.21.e41_ref43
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-4306
– volume: 6
  start-page: 11150
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref54
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3441
– volume: 3
  start-page: 279
  year: 2011
  ident: 10.4048/jbc.2018.21.e41_ref58
  publication-title: EMBO Mol Med
  doi: 10.1002/emmm.201100136
– volume: 28
  start-page: 506
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref79
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2016.02.006
– volume: 131
  start-page: 385
  year: 2012
  ident: 10.4048/jbc.2018.21.e41_ref45
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-011-1409-2
– volume: 1238
  start-page: 3
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref17
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-1804-1_1
– volume: 6
  start-page: 2
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref22
  publication-title: Front Genet
  doi: 10.3389/fgene.2015.00002
– volume: 28
  start-page: e563
  year: 2010
  ident: 10.4048/jbc.2018.21.e41_ref35
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.1010
– volume: 121
  start-page: 2750
  year: 2011
  ident: 10.4048/jbc.2018.21.e41_ref12
  publication-title: J Clin Invest
  doi: 10.1172/JCI45014
– volume: 68
  start-page: 7
  year: 2018
  ident: 10.4048/jbc.2018.21.e41_ref1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
– volume: 7
  start-page: 15
  year: 2008
  ident: 10.4048/jbc.2018.21.e41_ref44
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-7-15
– volume: 38
  start-page: 30
  year: 2018
  ident: 10.4048/jbc.2018.21.e41_ref29
  publication-title: Breast
  doi: 10.1016/j.breast.2017.11.006
– volume: 10
  start-page: 765
  year: 2018
  ident: 10.4048/jbc.2018.21.e41_ref77
  publication-title: Epigenomics
  doi: 10.2217/epi-2018-0008
– volume: 20
  start-page: 3254
  year: 2013
  ident: 10.4048/jbc.2018.21.e41_ref28
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-013-3205-1
– volume: 54
  start-page: 1656
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref53
  publication-title: Mol Carcinog
  doi: 10.1002/mc.22237
– volume: 6
  start-page: 33435
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref37
  publication-title: Sci Rep
  doi: 10.1038/srep33435
– volume: 5
  start-page: 9864
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref50
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2454
– volume: 1
  start-page: e17
  year: 2012
  ident: 10.4048/jbc.2018.21.e41_ref27
  publication-title: Oncogenesis
  doi: 10.1038/oncsis.2012.17
– volume: 6
  start-page: 5987
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref65
  publication-title: Nat Commun
  doi: 10.1038/ncomms6987
– volume: 16
  start-page: 700
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref74
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2683-5
– volume: 10
  start-page: R46
  year: 2008
  ident: 10.4048/jbc.2018.21.e41_ref42
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2098
– volume: 108
  start-page: 2172
  year: 2013
  ident: 10.4048/jbc.2018.21.e41_ref31
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.144
– volume: 147
  start-page: 639
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref76
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-014-3089-1
– volume: 291
  start-page: 23756
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref71
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M116.738666
– volume: 19
  start-page: 223
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref16
  publication-title: J Breast Cancer
  doi: 10.4048/jbc.2016.19.3.223
– volume: 12
  start-page: R36
  year: 2010
  ident: 10.4048/jbc.2018.21.e41_ref41
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2590
– volume: 7
  start-page: 53997
  year: 2016
  ident: 10.4048/jbc.2018.21.e41_ref69
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9804
– volume: 641
  start-page: 248
  year: 2018
  ident: 10.4048/jbc.2018.21.e41_ref89
  publication-title: Gene
  doi: 10.1016/j.gene.2017.10.018
– volume: 22
  start-page: 1026
  year: 2013
  ident: 10.4048/jbc.2018.21.e41_ref3
  publication-title: Breast
  doi: 10.1016/j.breast.2013.08.007
– volume: 6
  start-page: 21730
  year: 2015
  ident: 10.4048/jbc.2018.21.e41_ref47
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4419
– volume: 7
  start-page: 1225
  year: 2012
  ident: 10.4048/jbc.2018.21.e41_ref34
  publication-title: Epigenetics
  doi: 10.4161/epi.22561
– volume: 16
  start-page: 19
  year: 2014
  ident: 10.4048/jbc.2018.21.e41_ref25
  publication-title: Curr Top Behav Neurosci
  doi: 10.1007/978-3-662-45758-0_255
– volume: 464
  start-page: 1071
  year: 2010
  ident: 10.4048/jbc.2018.21.e41_ref52
  publication-title: Nature
  doi: 10.1038/nature08975
– volume: 490
  start-page: 61
  year: 2012
  ident: 10.4048/jbc.2018.21.e41_ref40
  publication-title: Nature
  doi: 10.1038/nature11412
– reference: 27029062 - Oncotarget. 2016 May 10;7(19):27158-75
– reference: 18221536 - Mol Cancer. 2008 Jan 25;7:15
– reference: 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
– reference: 23881244 - Mol Cell Biochem. 2013 Sep;381(1-2):61-8
– reference: 21874112 - Curr Oncol. 2011 Aug;18(4):161-4
– reference: 27721871 - J Breast Cancer. 2016 Sep;19(3):223-230
– reference: 27977696 - PLoS One. 2016 Dec 15;11(12):e0167016
– reference: 29202330 - Breast. 2018 Apr;38:30-38
– reference: 21965309 - Breast Dis. 2010;32(1-2):5-24
– reference: 17320506 - Cell. 2007 Feb 23;128(4):683-92
– reference: 20393566 - Nature. 2010 Apr 15;464(7291):1071-6
– reference: 25574598 - Nat Commun. 2015 Jan 09;6:5987
– reference: 21472990 - EMBO Mol Med. 2011 May;3(5):279-90
– reference: 27250026 - Oncotarget. 2016 Jun 28;7(26):40418-40436
– reference: 24751816 - Nat Rev Drug Discov. 2014 May;13(5):337-56
– reference: 29263092 - J Biol Chem. 2018 Feb 9;293(6):2125-2136
– reference: 25208879 - Clin Cancer Res. 2015 Apr 1;21(7):1688-98
– reference: 21818544 - J Mammary Gland Biol Neoplasia. 2011 Sep;16(3):257-70
– reference: 25224916 - Breast Cancer Res Treat. 2014 Oct;147(3):639-51
– reference: 23975317 - Ann Surg Oncol. 2013 Oct;20(10):3254-8
– reference: 25996380 - Cancer Biol Ther. 2015;16(6):856-65
– reference: 29313949 - CA Cancer J Clin. 2018 Jan;68(1):7-30
– reference: 22613095 - Breast Cancer Res. 2012 May 21;14(3):R79
– reference: 22626806 - Am J Pathol. 2012 Jul;181(1):257-67
– reference: 24925028 - Carcinogenesis. 2014 Oct;35(10):2254-63
– reference: 26633365 - Int J Mol Sci. 2015 Nov 30;16(12):28347-76
– reference: 29486795 - J Hematol Oncol. 2018 Feb 27;11(1):32
– reference: 23552734 - Oncogenesis. 2012 Jul 02;1:e17
– reference: 19789319 - Clin Cancer Res. 2009 Oct 1;15(19):6148-57
– reference: 27935867 - Oncotarget. 2017 Jan 31;8(5):7598-7613
– reference: 23970019 - Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23
– reference: 23069641 - Epigenetics. 2012 Nov;7(11):1225-9
– reference: 26975198 - Breast Cancer Res. 2016 Mar 15;18(1):33
– reference: 23558900 - Br J Cancer. 2013 May 28;108(10):2172-7
– reference: 24114677 - J Pathol. 2014 Jan;232(2):142-50
– reference: 24911873 - PLoS One. 2014 Jun 09;9(6):e98930
– reference: 25417703 - Oncogene. 2015 Aug 13;34(33):4333-46
– reference: 27283767 - Oncotarget. 2016 Aug 16;7(33):53997-54009
– reference: 25808524 - J Cell Physiol. 2015 Nov;230(11):2683-94
– reference: 25177489 - J Cancer Ther Res. 2014 Mar 19;3(2):1-11
– reference: 29156719 - Oncotarget. 2017 Jul 12;8(49):85276-85289
– reference: 20679605 - J Clin Oncol. 2010 Oct 10;28(29):e563-4; author reply e565-6
– reference: 27581651 - BMC Cancer. 2016 Aug 31;16:700
– reference: 27227949 - Medicine (Baltimore). 2016 May;95(21):e3783
– reference: 26876786 - Cell Signal. 2016 May;28(5):506-515
– reference: 24632568 - Oncotarget. 2014 Mar 15;5(5):1174-84
– reference: 25421652 - Methods Mol Biol. 2015;1238:3-25
– reference: 27310713 - PLoS One. 2016 Jun 16;11(6):e0157368
– reference: 26088362 - Carcinogenesis. 2015 Sep;36(9):1051-60
– reference: 26392359 - Cell Oncol (Dordr). 2015 Dec;38(6):433-42
– reference: 27817751 - Expert Rev Mol Med. 2016 Nov 7;18:e18
– reference: 27956838 - Onco Targets Ther. 2016 Nov 11;9:6921-6933
– reference: 27717206 - Genes Chromosomes Cancer. 2017 Feb;56(2):147-158
– reference: 27671774 - Sci Rep. 2016 Sep 27;6:33435
– reference: 25641231 - Nat Commun. 2015 Feb 02;6:5899
– reference: 10963602 - Nature. 2000 Aug 17;406(6797):747-52
– reference: 26775620 - Nat Rev Cancer. 2016 Feb;16(2):110-20
– reference: 24063766 - Breast. 2013 Dec;22(6):1026-33
– reference: 25516208 - Mol Med Rep. 2015 Apr;11(4):3155-9
– reference: 22236695 - Curr Opin Immunol. 2012 Apr;24(2):207-12
– reference: 18485221 - Breast Cancer Res. 2008;10(3):R46
– reference: 29371976 - Oncotarget. 2017 Dec 12;8(69):114156-114172
– reference: 25849487 - PLoS One. 2015 Apr 07;10(4):e0120936
– reference: 19366799 - Cancer Res. 2009 May 1;69(9):3802-9
– reference: 20565864 - Breast Cancer Res. 2010;12(3):R36
– reference: 29038000 - Gene. 2018 Jan 30;641:248-258
– reference: 26078338 - Oncotarget. 2015 Aug 28;6(25):21730-9
– reference: 25738536 - Molecules. 2015 Mar 02;20(3):3898-941
– reference: 28061448 - Oncotarget. 2017 Mar 21;8(12):19478-19490
– reference: 21633166 - J Clin Invest. 2011 Jul;121(7):2750-67
– reference: 21359954 - Breast Cancer Res Treat. 2012 Jan;131(2):385-99
– reference: 23000897 - Nature. 2012 Oct 4;490(7418):61-70
– reference: 25296969 - Oncotarget. 2014 Oct 30;5(20):9864-76
– reference: 26735014 - Nature. 2016 Jan 21;529(7586):413-417
– reference: 21278442 - Oncologist. 2011;16 Suppl 1:61-70
– reference: 25888415 - Breast Cancer Res. 2015 Mar 07;17:33
– reference: 25328122 - Mol Carcinog. 2015 Dec;54(12):1656-67
– reference: 27223259 - Oncotarget. 2016 Jun 21;7(25):38270-38281
– reference: 29480027 - Epigenomics. 2018 Jun;10(6):765-783
– reference: 21067385 - N Engl J Med. 2010 Nov 11;363(20):1938-48
– reference: 25887482 - Breast Cancer Res. 2015 Mar 20;17:43
– reference: 29050361 - Oncotarget. 2017 Aug 1;8(41):71285-71291
– reference: 26617826 - Int J Clin Exp Pathol. 2015 Sep 01;8(9):11076-83
– reference: 23801749 - Cancer Res. 2013 Oct 1;73(19):5858-68
– reference: 25883211 - Oncotarget. 2015 May 10;6(13):11150-61
– reference: 26328265 - Am J Cancer Res. 2015 Jun 15;5(7):2330-43
– reference: 24318963 - Curr Top Behav Neurosci. 2014;16:19-48
– reference: 22906839 - Mol Aspects Med. 2013 Jul-Aug;34(4):753-64
– reference: 25674102 - Front Genet. 2015 Jan 26;6:2
– reference: 29458327 - BMC Genomics. 2018 Feb 20;19(1):150
– reference: 26037781 - Mol Cancer Ther. 2015 Aug;14(8):1848-57
– reference: 19927298 - J Pathol. 2010 Jan;220(2):263-80
– reference: 25410431 - Int J Cancer. 2015 Dec 15;137(12):2785-94
– reference: 27650498 - J Biol Chem. 2016 Nov 4;291(45):23756-23768
SSID ssj0064377
Score 2.3650644
SecondaryResourceType review_article
Snippet Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 233
SubjectTerms Review
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9BJ8Fe-B6ELxmJB3hwusTOh3lbu1XTYNUEqzTEQ2Q7Dhut0qpNhcZfz12SFqoKIXiKolwSJ3f2_c53_hngdWBCI3RkuULny2Ua51yn2vFcJOgwTFLENYnr6TA-HsmTi-jiV1Wl-2asP553P12XerZw3UNd6e7Z4aA-Etw-6fW7KMPDgIcCw8C8uAk7MSWXOrAzGp4dfK5XQGIvRiRc7yy3j23AIXe_4fWRxFNLL0HHl_ph4DsZbLqkLZy5XS55e1nO9PV3PZn85osGd-HLakVPU4Iy9peV8e2PbYLH__jMe3CnhajsoLGp-3DDlQ_g1mmbhH8IH9G02NGMaDxpBeSCTQt2PqcJez50X2sicabLnPX0Qk_4h6uxYz0qfa9Yn0xs_o61pFDs_WpC7xGMBkfn_WPebs3ArVCi4pGNUmutTKwzOcZ0SlqTFpGyxPgWpaZI46RQUklhiIIQR3dl8kBqIRPEOIiR9qBTTkv3BFheYMSoYidkjpJRbGIVmMIZIl0qED944K-0k9mWt5y2z5hkGL-QOjP8URmpMwuDDNXpwZv1DbOGsuPPoq9W6s6wW1GuRJduulzg9QCBrMD40YPHjfrXD6tTvYhUPUg2DGMtQJTdm1fKq8uauhvxY4qIyYO3axP6Wxuf_oPsM9ils6YG7jl0qvnSvUDQVJmXbe_4CYboETo
  priority: 102
  providerName: Unpaywall
Title The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
URI https://www.ncbi.nlm.nih.gov/pubmed/30275851
https://www.proquest.com/docview/2115753149
https://pubmed.ncbi.nlm.nih.gov/PMC6158152
http://ejbc.kr/Synapse/Data/PDFData/0096JBC/jbc-21-233.pdf
UnpaywallVersion publishedVersion
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: DOA
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: 5-W
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 20250630
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: M48
  dateStart: 20110301
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3dS-QwEB9EQX05TvzqfSwRfNCHFLpN2-ReDhVF_FhEXNCnkqTpnVq6e_vBnf_9zbTd6qLic6ZpmZl0fpNJfgOwG5iuCXVkucLgy4WMM66ldjwLEwwYJsnjisT1shef9sXZbXT73A6oUeD4zdSO-kn1R4X_78_TT1zwiF99QbSzD4a4CAPpdwPf0SX2JQxLXXLxS9GWFKhAVXVaSXCFI0qOa56ftyZYheWqmiejYD5avYKgr09SrkzLoX76q4viRZg6-QyfGnzJDmqHWIMFV67DNToDOx4S8SbdWRyzQc5uRrTFznvuV0X9zXSZsUM91gW_uH907JAOq0_YETnF6AdraJzY-WwLbgP6J8c3R6e8aabAbajCCY9sJK21IrHOZJiFKWGNzCNliaMtkiaXcZIroURoiDQQ_8fKZIHQoUgQlSCq2YTFclC6bWBZjjmeil0oMpSMYhOrwOTOEE1SjhHfA3-mtNQ2TOPU8KJIMeMghaeo8JQUnnaDFBXuwV77wLAm2XhfdGdmhRQXAlU3dOkG0zGOBwg9Q8z4PNiqrdJONjOnB8mcvVoBItmeHynvf1dk24j4JGIcD_Zby370jV_eff9XWCW5-ozaN1icjKbuO4KaielUmwGdymU71Z5TB5b6vauDu_-mtvUe
linkProvider Scholars Portal
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9BJ8Fe-B6ELxmJB3hwusTOh3lbu1XTYNUEqzTEQ2Q7Dhut0qpNhcZfz12SFqoKIXiKolwSJ3f2_c53_hngdWBCI3RkuULny2Ua51yn2vFcJOgwTFLENYnr6TA-HsmTi-jiV1Wl-2asP553P12XerZw3UNd6e7Z4aA-Etw-6fW7KMPDgIcCw8C8uAk7MSWXOrAzGp4dfK5XQGIvRiRc7yy3j23AIXe_4fWRxFNLL0HHl_ph4DsZbLqkLZy5XS55e1nO9PV3PZn85osGd-HLakVPU4Iy9peV8e2PbYLH__jMe3CnhajsoLGp-3DDlQ_g1mmbhH8IH9G02NGMaDxpBeSCTQt2PqcJez50X2sicabLnPX0Qk_4h6uxYz0qfa9Yn0xs_o61pFDs_WpC7xGMBkfn_WPebs3ArVCi4pGNUmutTKwzOcZ0SlqTFpGyxPgWpaZI46RQUklhiIIQR3dl8kBqIRPEOIiR9qBTTkv3BFheYMSoYidkjpJRbGIVmMIZIl0qED944K-0k9mWt5y2z5hkGL-QOjP8URmpMwuDDNXpwZv1DbOGsuPPoq9W6s6wW1GuRJduulzg9QCBrMD40YPHjfrXD6tTvYhUPUg2DGMtQJTdm1fKq8uauhvxY4qIyYO3axP6Wxuf_oPsM9ils6YG7jl0qvnSvUDQVJmXbe_4CYboETo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Epigenetics+of+Triple-Negative+and+Basal-Like+Breast+Cancer%3A+Current+Knowledge&rft.jtitle=Journal+of+breast+cancer&rft.au=Temian%2C+Daiana+Cosmina&rft.au=Pop%2C+Laura+Ancuta&rft.au=Irimie%2C+Alexandra+Iulia&rft.au=Berindan-Neagoe%2C+Ioana&rft.date=2018-09-01&rft.issn=1738-6756&rft.volume=21&rft.issue=3&rft.spage=233&rft_id=info:doi/10.4048%2Fjbc.2018.21.e41&rft_id=info%3Apmid%2F30275851&rft.externalDocID=30275851
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-6756&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-6756&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-6756&client=summon